Renal Cell Carcinoma
Advertisement
Overall survival, TFS, TFS with and without toxicity, and time to all protocol therapy cessation were quantified.
Kidney injury molecule-1 is a transmembrane protein that can serve as a urinary indicator of acute renal tubular injury.
Researchers analyzed the connection between the outcomes and specific predictors of interest.
In patients with RCC, around 20% demonstrate non-clear cell histology, including various histology types.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Approximately 82,000 new cases of RCC are diagnosed each year in the US, but effective early detection methods are lacking.
Drs. Joyce and Khanna examine the utility of a deep learning algorithm for automated renal volume calculation.
ICIs improves OS for patients with mRCC and sarcomatoid features who undergo CN, regardless of the timing of surgery.
Drs. Joyce and Pierorazio weigh appropriate surveillance versus primary intervention for clinical T1a kidney tumors.
Previous studies investigating adjuvant therapy in patients with RCC have not included those with PSM.
Researchers completed a comprehensive evaluation of features that can serve as biomarkers of response to ICB therapy in mRCC.
Patients underwent treatment with lenvatinib plus everolimus as a second-line therapy.
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
A new study by an international research team has identified new susceptibility regions associated with RCC development risk.
Dr. Swami investigated the efficacy of cabozantinib in combination with immune checkpoint inhibitors for mccRCC.
Dr. Zakharia continues his commentary on the BTCRC-GU16-043 study investigating guadecitabine and durvalumab in accRCC.
Dr. Zakharia explains why guadecitabine plus durvalumab may be a good treatment approach in patients with advanced RCC.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Drs. Braun and Beckermann stress the importance of adopting an integrative approach to biomarker-based research in RCC.
Drs. Braun and Beckermann review JAVELIN Renal 101, focusing on the impact of avelumab and axitinib treatment on RCC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.